Bio-Rad Laboratories, Inc. Class A Common Stock vs Vertiv Holdings Co — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Vertiv Holdings Co trades at $306.5 (market cap $117.49B). The key difference: Vertiv Holdings Co is far larger — about 14.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Vertiv Holdings Co pays a 0.08% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | VRT | |
|---|---|---|
Market Cap | $8.02B | $117.49B |
Sector | Health | Technology |
52-Week High | $339.75 | $376.23 |
52-Week Low | $241.71 | $121.82 |
Enterprise Value | $7.84B | $118.25B |
Dividend Yield | — | 0.08% |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →